Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

• Status: Completed
• Trial end date: 2017-11-10

Summary

Drug-drug interaction study in healthy men and women not of childbearing potential. Assess the effect of BMS-986195 on the pharmacokinetics of methotrexate, caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin. Collect data on safety of BMS-986195 and methotrexate, caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin. Collect data on multiple-dose pharmacodynamics of BMS-986195.

• Phase: Phase 1

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Branebrutinib; Caffeine; Digoxin; Flurbiprofen; Leucovorin; Methotrexate; Midazolam; Montelukast; Omeprazole; Pravastatin